| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 |
| filingDate |
2018-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5556ae6ca6d56b4becf38592676a3e27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0ba67c4a2e07a0901166c8713f564e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2be8eb88f30f476e6213c3077e4065ca |
| publicationDate |
2019-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201919626-A |
| titleOfInvention |
Pharmaceutical composition |
| abstract |
The invention relates to a pharmaceutical composition for oral administration, which comprises a non-biliary farnesol X receptor (FXR) agonist 2-[( 1R, 3R, 5S ) -3-({5-cycloprop Yl-3- [2- (trifluoromethoxy) phenyl] -1,2-oxazol-4-yl} methoxy) -8-azabicyclo [3.2.1] oct-8-yl ] -4-fluoro-1,3-benzothiazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof and at least one lipid excipient; it relates to a capsule for oral administration containing the pharmaceutical composition; It relates to the use of the pharmaceutical composition for the treatment of FXR-mediated disorders or conditions; and to the method of preparing the pharmaceutical composition. |
| priorityDate |
2017-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |